Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

Фасинумаб (REGN475)

Рандомизированное, двойное слепое, контролируемое плацебо и напроксеном исследование 3 фазы для оценки эффективности и безопасности различных доз фасинумаба при применении у пациентов с болью, вызванной остеоартритом коленного или тазобедренного сустава

Разрешение№ 596 от 15.11.2017
Номер протоколаR475-OA-1611
ФазаФаза III
Участников по плану600
Сроки15.11.2017 — 30.06.2022
Страна разработчикаСША
Начало: 15 ноября 2017Окончание: 30 июня 2022
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/permit/ru/596/2017-11-15/

Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 600 чел. в стране «Россия».
  • Центров в реестре: 11 в 7 городах. Список — ниже на странице.
  • Плановая дата окончания (06.2022) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 23 · невключение: 17

Критерии включения

  • include, but are not limited to, the following:
  • Year 1:
  • Male and female patients, at least 18 years of age, at screening
  • A clinical diagnosis of OA of the knee or hip based on the American College of Rheumatology criteria with radiologic evidence of OA (K-L score ≥2 for the index joint) at the screening visit
  • Moderate to severe pain in the index joint defined at both the screening and randomization visits
  • Willing to discontinue current pain medications and to adhere to study requirements for rescue treatments (acetaminophen/paracetamol) to be taken as needed with a maximum daily dose of 2500 mg (countries where 500 mg strength tablets/capsules are available) or 2600 mg (countries where 325 mg strength tablets/capsules are available)
  • A history of at least 12 weeks of analgesics use for pain due to OA of the knee or hip, as defined by:
  • Inadequate pain relief from acetaminophen/paracetamol AND
  • Intolerance to or inadequate pain relief from opioid or tramadol therapy, unwillingness to take opioid or tramadol therapy for a medically acceptable reason, or lack of access to an opioid or to tramadol
  • Currently using a stable dose of NSAID.
  • Willing to discontinue glucosamine sulfate and chondroitin sulfate treatments during the initial 16 weeks of treatment
  • Stable treatment with glucosamine sulfate and chondroitin sulfate treatments must be stopped during the pre-randomization period
  • Consent to allow all radiographs and medical/surgical/hospitalization records of care received elsewhere prior to and during the study period to be shared with the investigator
  • Willing to maintain current activity and exercise levels throughout the study
  • Willing and able to comply with clinic visits and study-related procedures and willing to provide follow-up information related to any JR surgery that occurs within the period of time covered by their intended participation in the study
  • Able to understand and complete study-related questionnaires
  • Year 2:
  • Note: Any Year 1 patient attending their week 52 visit on or after 26 March 2020 will no longer have the option to enroll into Year 2.
  • Completed the treatment period of Year 1
  • Did not permanently discontinue study drug during Year 1
  • Received no less than 10 of the 13 planned doses of SC study drug during the treatment period of Year 1
  • Provide informed consent for Year 2
  • Willing to continue to maintain current activity and exercise levels throughout Year 2

Критерии невключения

  • include, but are not limited to, the following:
  • Non-compliance with the Numeric Rating Scale (NRS) recording during the pre-randomization period
  • History or presence at the screening visit of non-OA inflammatory joint disease, Paget's disease of the spine, pelvis or femur, neuropathic disorders, multiple sclerosis, fibromyalgia, tumors or infections of the spinal cord, or renal osteodystrophy
  • History or presence on imaging of arthropathy, neuropathic joint arthropathy, hip or knee dislocation, extensive subchondral cysts, significant bone collapse or bone loss, or pathologic fractures
  • Trauma to the index joint within 3 months prior to the screening visit
  • Signs or symptoms of carpal tunnel syndrome within 6 months of screening
  • Patient is not a candidate for MRI
  • Is scheduled for a JR surgery to be performed during the study period or who would be unwilling or unable to undergo JR surgery if needed
  • History or presence at the screening visit of autonomic or diabetic neuropathy, or other peripheral neuropathy, including reflex sympathetic dystrophy
  • History or diagnosis of chronic autonomic failure syndrome including pure autonomic failure, multiple system atrophy
  • History of naproxen intolerance, or existence of a medical condition that is high risk for naproxen-associated complications
  • Resting heart rate of <50 beats per minute (bpm) or >100 bpm at the screening or randomization visits
  • History or presence of 2nd or 3rd degree heart block, 1st degree heart block with abnormal Complex of Q, R, and S waves on an electrocardiogram (QRS) complex, or bifascicular block by ECG assessment at the screening visit
  • History or presence of orthostatic hypotension at the screening, prerandomization, or randomization visits
  • History of poorly controlled hypertension
  • Use of systemic corticosteroid within 30 days prior to the screening visit. Intra-articular corticosteroids in the index joint within 12 weeks prior to the screening visit, or to any other joint within 30 days prior to the screening visit
  • Exposure to an anti-Nerve growth factor (NGF) antibody prior to the screening visit or known sensitivity or intolerance to anti-NGF antibodies

Источник: ClinicalTrials.gov, NCT03161093 · запись обновлена в реестре 14 ноября 2022.

Дизайн и результаты

ДизайнРандомизированное, тройное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)3 307
Что измеряют — первичные конечные точки (4), вторичных — 45
  • Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q4W Compared With That of Participants Treated With Placebo — Baseline to Week 16
  • Change in the WOMAC Physical Function Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg Q4W Compared With That of Participants Treated With Placebo — Baseline to Week 16
  • Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q8W Compared With That of Participants Treated With Placebo — Baseline to Week 16
  • Change in the WOMAC Physical Function Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg Q8W Compared With That of Participants Treated With Placebo — Baseline to Week 16

Цель исследования

The primary objective of the study is to evaluate the efficacy of fasinumab compared with placebo, when administered for up to 16 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.

The secondary objectives of the study are:

1. To evaluate the efficacy of fasinumab compared with naproxen, when administered for up to 16 weeks in patients with pain due to OA of the knee or hip
2. To evaluate the efficacy of fasinumab compared with placebo, when administered for up to 44 weeks in patients with pain due to OA of the knee or hip
3. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 16 weeks in patients with pain due to OA of the knee or hip
4. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 52 weeks in patients with pain due to OA of the knee or hip
5. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 104 weeks in patients with pain due to OA of the knee or hip
6. To evaluate the pharmacokinetic (PK) profile of fasinumab administered to patients with pain due to OA of the knee or hip for up to 52 weeks
7. To evaluate the PK profile of fasimumab administered to patients with pain due to OA of the knee or hip for up to 104 weeks
8. To evaluate the immunogenicity of fasinumab administered to patients with pain due to OA of the knee or hip for up to 52 weeks
9. To evaluate the immunogenicity of fasinumab administered to patients with pain due to OA of the knee or hip for up to 104 weeks
10. To evaluate the efficacy of fasinumab compared with naproxen, when administered for up to 44 weeks in patients with pain due to OA of the knee or hip

Области и заболевания

Где проходит

11 центров в 7 городах

Откуда эта информация

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.